Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


15th Asia Pacific Oncologists Annual Meeting

Tokyo, Japan

Juan Pablo Marquez

Juan Pablo Marquez

Sonora Cancer Research Centre, USA


Dr. Juan Pablo Marquez Manriquez, M.D. is a Medical Oncologist with training in Mexico, California and Seattle, Washington. His passion for Immunology and Oncology emerged from the very early stages of his life, as he prepared in pre-medicine by studying first Clinical Pharmacy and later medicine. He is currently developing projects for the prevention of gastrointestinal cancer in the CICS USA Seattle campus. He is currently specializing in the prevention of recurrence of tumors of high clinical impact such as ovarian, triple negative breast cancer, inflammatory breast cancer, colorectal and multiple myeloma. Since 2002, he has presented his scientific achievements at multiple international conferences led by AACR, ASCO, AAI, SITC and ESMO. He worked as a medical doctor at the Tumor Vaccine Group of the University of Washington. Dr. Marquez Manriquez is Binational Medical Director of the Binational Alliance in ImmunoOncology of Seattle, Sonora and Miami, including the Cancer Research Center in Sonora (CICS Sonora) both at the Ciudad Obregon Sonora campus and at the Seattle Washington campus (CICS USA), although his based in Seattle. In coordination with CICS and various institutions at the international level, CICS is developing through the investigations of Dr. Juan Pablo Marquez and CICS scientific medical team preventive vaccines to prevent pediatric and adult cancer and their recurrences. Importantly he is focus on combo therapies including but not limited to multi peptide immunotherapy targeting clinically relevant targets such as Ape-1, Fascin, RCAS1, EGFR, Survivin, VCP, Bcl-2, etc. in refractory and progressive tumors. The Binational Immuno Oncology of Seattle, Sonora and Miami are also generating combination of therapies that will allow for longer remissions and fewer recurrences for different types of tumors such as ovarian, sarcomas, neurotumors and gastrointestinal tumors.


Abstract : Multi-peptide immunotherapy in combination with immunogenic chemotherapy in refractory cancer patients